Shire PLC (SHPG) Downgraded to “Strong Sell” at BidaskClub
Shire PLC (NASDAQ:SHPG) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday.
Several other research firms have also recently commented on SHPG. Royal Bank Of Canada set a $221.00 target price on shares of Shire PLC and gave the company a “buy” rating in a research note on Thursday, May 18th. Sanford C. Bernstein reissued a “market perform” rating and set a $210.00 target price on shares of Shire PLC in a research note on Thursday, July 13th. HSBC Holdings plc raised shares of Shire PLC from a “reduce” rating to a “hold” rating in a research note on Thursday, July 6th. Jefferies Group LLC restated a “buy” rating and set a $216.00 price objective (down previously from $239.00) on shares of Shire PLC in a research report on Friday, June 9th. Finally, Stifel Nicolaus reduced their price objective on shares of Shire PLC from $250.00 to $245.00 and set a “buy” rating for the company in a research report on Friday, June 9th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $223.18.
Shire PLC (NASDAQ:SHPG) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.53 by $0.20. The firm had revenue of $3.75 billion for the quarter. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The firm’s quarterly revenue was up 54.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.38 EPS.
TRADEMARK VIOLATION NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2017/08/07/shire-plc-shpg-downgraded-to-strong-sell-at-bidaskclub.html.
Several hedge funds and other institutional investors have recently made changes to their positions in SHPG. Vanguard Group Inc. boosted its position in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after buying an additional 13,665 shares during the last quarter. BlackRock Inc. boosted its stake in Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Janus Capital Management LLC boosted its stake in Shire PLC by 10.7% in the first quarter. Janus Capital Management LLC now owns 1,365,226 shares of the biopharmaceutical company’s stock valued at $237,854,000 after buying an additional 132,446 shares in the last quarter. Boston Partners boosted its stake in Shire PLC by 80.7% in the first quarter. Boston Partners now owns 1,359,151 shares of the biopharmaceutical company’s stock valued at $236,805,000 after buying an additional 606,814 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Shire PLC by 19.7% in the first quarter. Bank of America Corp DE now owns 1,326,114 shares of the biopharmaceutical company’s stock valued at $231,049,000 after buying an additional 218,291 shares in the last quarter. Institutional investors own 21.04% of the company’s stock.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.